Seres Therapeutics(MCRB) - 2024 Q4 - Earnings Call Presentation
Seres Therapeutics Investor Presentation March 2025 Transforming patient outcomes using proprietary consortia of live biotherapeutics Seres Therapeutics Investor Presentation March 2025 Strong Foundation Positive SER-155 Phase 1b Data in Allo-HSCT Blockbuster SER-155 Opportunity • Initial SER-155 development in allo-HSCT • Potential to initiate multiple clinical trials for additional indications • SER-155 represents multi- billion net sales opportunity across indications (e.g., autologous-HSCT, blood cancer ...